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Implantable Atrial Defibrillator
With a Single-Pass Dual-Electrode Lead
Hung-Fat Tse, MBBS,* Chu-Pak Lau, MD,* Barry M. Yomtov, MSEBE,† Gregory M. Ayers, MD, PHD†
Hong Kong, China and Redmond, Washington
OBJECTIVES We examined the feasibility and efficacy of using a single-pass, dual-electrode (Solo) lead for
atrial fibrillation (AF) detection and defibrillation.
BACKGROUND The efficacy and safety of an implantable atrial defibrillator (IAD) has been extensively
studied; however, separate right atrial (RA) and coronary sinus (CS) defibrillation leads are
used for the present system.
METHODS We studied the use of the Solo lead for AF detection and defibrillation in 17 patients who
underwent cardioversion of chronic AF. The Solo lead with a proximal 6-cm RA electrode
and a distal 6-cm spiral-shaped CS electrode were positioned into the CS with the RA
electrode against the anterolateral RA wall. The RA-CS electrogram signal amplitudes were
measured and the efficacy of the Solo lead for AF detection and defibrillation was assessed by
using an external version of the IAD.
RESULTS The leads were inserted in all patients without complication (mean fluoroscopy time: 13.3 6
6.8 min). The mean RA-CS signal amplitude was 484 6 229 mV during sinus rhythm and
274 6 88 mV during AF (p , 0.05). All patients had satisfactory atrial signal amplitude to
allow accurate detection of sinus rhythm. Successful cardioversion was achieved in 16/17
(94%) patients with an atrial defibrillation threshold of 320 6 70 V (5.5 6 2.7 J). Insufficient
interelectrode spacing resulted in suboptimal electrode locations, associated with a lower atrial
signal amplitude, a higher atrial defibrillation threshold and diaphragmatic stimulation.
CONCLUSIONS These results suggest a simplified lead configuration with optimal interelectrode spacing can
be used with an IAD for AF detection and defibrillation. (J Am Coll Cardiol 1999;33:
1974–80) © 1999 by the American College of Cardiology
Recent studies of animals (1) and humans (2–7) have shown
that low energy, biatrial, R-wave synchronized shocks de-
livered transvenously are safe and effective for cardioversion
of atrial fibrillation (AF). These findings prompted the
development of an implantable atrial defibrillator (IAD) as
a new therapeutic prospect for patients with drug refractory
AF (8,9). To minimize atrial defibrillation threshold, with
its implication on battery longevity and patient tolerability,
electrodes should be positioned so that they encompass both
atria. Previous studies show that this is best achieved with
one electrode in the right atrium (RA) and one in the distal
coronary sinus (CS) (1,3,10). However, a disadvantage of
the currently available lead system is the need for separate
RA and CS leads. The need for multiple leads increases the
cost, time of the implantation procedure and potential risks
of perioperative and late complications. The development of
a single-pass lead with both the RA and CS defibrillation
electrodes on the same lead would simplify the implantation
of an IAD. The aims of this study were to investigate the
following: 1) the feasibility and efficacy of using a single-
pass, dual-electrode defibrillation lead for AF detection and
defibrillation; 2) the effects of different electrode locations
resulting from different interelectrode spacing on AF detec-
tion and defibrillation, and 3) the lead stability and changes
in atrial signal amplitude during changes in patient posture.
METHODS
Study population. All patients gave written informed con-
sent before the procedure, and the study protocol was
approved by the local ethics committee. Transvenous atrial
defibrillation was performed in 17 patients (15 males, two
female; mean age 61 6 10 years, range 34 to 76) with
electrocardiographically documented persistent AF (mean
duration of AF, 24 6 16 months, range: 7 to 60 months).
After detailed medical history and physical examination, all
patients underwent a preprocedure evaluation consisting of
a 12-lead electrocardiogram, 24-h Holter monitoring, chest
X ray, transthoracic and transesophageal echocardiography,
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and routine laboratory and thyroid function tests. Patients
with the following conditions were excluded from this
study: 1) reversible causes of atrial fibrillation, such as
electrolyte imbalance and hyperthyroidism; 2) clinically
significant valvular heart disease; 3) unstable angina or
recent myocardial infarction within the past 6 months; 4)
New York Heart Association class III or IV heart failure,
and 5) echocardiographic evidence of left atrial thrombi.
Underlying heart disease was present in 12 (71%) patients,
including hypertension (n 5 9), thyroid heart disease (n 5
1), dilated cardiomyopathy (n 5 1) and mild mitral valvular
heart disease (n 5 1). Their mean left ventricular ejection
fraction and left atrial diameter was 61 6 10% and 4.68 6
0.82 cm, respectively. All patients were treated with oral
amiodarone and with oral anticoagulation using warfarin to
achieve an international normalized ratio of 2–3 for at least
3 weeks before the procedure.
Defibrillation lead placement. Patients were brought to
the cardiac electrophysiology laboratory in the postabsorp-
tive, nonsedated state. Local anesthesia at the sites used for
catheter insertion was achieved by subcutaneous infiltration
of bupivacaine (0.25%). An 11-F and a 7-F sheath were
introduced into the left subclavian vein using two separate
venapunctures. A custom-made single-pass passive fixation
implantable defibrillation lead (Perimeter Solo Model 7305,
7309 or 7312, InControl, Redmond, Washington) was used
for testing. The overall length of the lead was either 75 cm
or 85 cm with a maximal diameter of 3.3 mm. This lead had
two elongated coil electrodes used for atrial fibrillation
detection and defibrillation. The proximal (RA) and distal
(CS) electrodes had a defibrillation coil electrode length of
6 cm and an electrode surface area of 7.1 cm2 and 4.5 cm2,
respectively. The distal defibrillation coil forms a pigtail-like
spring coil of 2.5 turns when the stylet is withdrawn (Fig. 1).
Leads with different interelectrode spacing (5 cm, 9 cm and
12 cm) were chosen at random and tested in different
patients. For defibrillation shock delivery, the RA electrode
served as the cathode and the CS electrode as the anode
with respect to the first phase of the shock.
With the use of a stiff stylet shaped with a gentle curve,
the lead was advanced into the CS under fluoroscopic
guidance. The lead was positioned to have the distal
electrode in the distal CS with the proximal electrodes
against the anterolateral RA wall whenever possible. A
ventricular passive fixation pacing lead (Model 4024,
Medtronic, Minneapolis, Minnesota) was placed in the
right ventricular apex for R-wave synchronization and
postshock pacing.
The IAD. The METRIX Defibrillation System Analyzer
(Model 2101 or 2102, InControl, Redmond, Washington)
was connected to the leads and was used to simulate the
functionality of the Metrix IAD. The device monitors the
intracardiac atrial (RA-CS vector) and ventricular (RV
bipolar) electrogram using specific AF detection and
R-wave synchronization algorithm, for AF detection and
for synchronized shock delivery. The details of these algo-
rithms of the IAD have been described previously (10–12).
After successful AF detection and R-wave synchronization,
R-wave synchronized biphasic shock of 3/3 ms (Model
2101) or 6/6 ms (Model 2102) can be delivered at selected
voltages, with a maximal intensity of 400 V.
Study protocol. Testing was performed after the patients
were sedated with intravenous midazolam (0.05 mg/kg) and
Abbreviations and Acronyms
AF 5 atrial fibrillation
CS 5 coronary sinus
IAD 5 implantable atrial defibrillator
RA 5 right atrium
Figure 1. Single-pass, dual-electrode implantable (Solo) lead used for transvenous atrial defibrillation. Note the spring coil of the coronary
sinus electrode after the stylet is withdrawn (bottom).
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pethidine (0.5 mg/kg), and additional doses were given as
required. The AF detection algorithm of the IAD was
tested, and data, including the 8 s of electrogram, were
stored for analysis of the electrogram signal amplitude.
Furthermore, in seven patients, the RA-CS electrograms
were evaluated using the AF detection algorithm during AF
and sinus rhythm while the patient assumed both a supine
and upright posture. All stored RA-CS electrograms were
evaluated after signal processing using a filter setting of 40
to 500 Hz for the determination of the mean atrial signal
amplitude during AF and sinus rhythm.
After running the AF detection algorithm, a test shock
of 20 V was delivered to assess the integrity of the
defibrillation system and to test the synchronization
process. R-wave synchronized, biphasic shocks (3/3 ms or
6/6 ms waveform) were delivered for cardioversion,
starting with a shock intensity of 180 V. The shock
intensity was increased in steps of 40 V until sinus
rhythm was restored (atrial defibrillation limit) or until a
shock of the maximal intensity deliverable from the
device (400 V) was reached. The shock with the lowest
intensity that resulted in successful conversion was con-
sidered the defibrillation threshold. After successful car-
dioversion, patients were then placed onto a tile table and
the stability of the lead position was assessed by fluoros-
copy during supine and upright (70° tilting for 5 min)
posture. At the end of the procedure, both the Solo lead
and the RV pacing lead were removed from all patients.
Statistical analysis. Results are expressed as mean 6 SD.
Statistical differences were analyzed with Fisher exact test
for categorical variables and Mann-Whitney U test for
continuous variables. Multiple comparisons between the
atrial signal amplitude at different electrode locations during
AF and sinus rhythm were performed using two-way
repeated measures analysis of variance, followed by Bonfer-
roni t tests for individual comparisons. A value of p , 0.05
was considered statistically significant.
RESULTS
Lead placement and electrode locations. The leads were
inserted in all patients through the left subclavian vein
without complication. The mean fluoroscopy time necessary
for lead placement was 13.3 6 6.8 min (range: 7 to
22.5 min). The final position of the defibrillation electrodes
was related to the interelectrode spacing of the lead used,
and these data are shown in Table 1. When a lead with
5-cm interelectrode spacing was used, the position of the
RA and CS electrodes in those patients was in the low
anterolateral RA and mid-CS, respectively (Fig. 2A). The
short interelectrode spacing between the two electrodes
prevented the CS electrode from being advanced into the
distal CS, as this would have resulted in the RA electrode
being positioned at or inside the ostium of the coronary
sinus. On the other hand, when a lead with a longer
interelectrode spacing (9 or 12 cm) was used, the position of
























1 62 M 28 4.97 5 MCS–LRA 3/3 303 3 65 319 338
2 34 M 7 4.33 5 MCS–LRA 3/3 360 4.2 71 310 594
3 60 M 24 5.17 5 MCS–LRA 3/3 .400 .5.5 60 151 273
4 54 M 36 4.46 5 MCS–LRA 3/3 380 4.7 60 141 864
5 57 F 14 5.6 9 DCS–MRA 3/3 280 2.6 58 173 330
6 59 F 8 4.75 5 MCS–LRA 3/3 400 5.2 62 379 303
7 60 M 18 6.4 9 DCS–MRA 3/3 260 4.1 74 361 540
8 73 M 18 5.7 9 MCS–LRA 6/6 400 10.4 67 172 260
9 53 M 24 4.05 9 DCS–MRA 6/6 220 2.9 71 390 1009
10 63 M 9 5.22 12 DCS–MRA 6/6 280 4.7 71 381 616
11 74 M 20 3.39 9 DCS–MRA 6/6 240 3.6 72 366 851
12 58 M 18 4.75 12 DCS–MRA 6/6 360 7.7 79 243 742
13 62 M 18 3.25 12 DCS–MRA 6/6 220 3 89 319 651
14 60 M 36 4.48 5 MCS–LRA 6/6 300 6.7 58 220 346
15 76 M 60 4.5 9 MCS–LRA 6/6 390 10.2 55 198 338
16 71 M 15 3.68 5 MCS–LRA 6/6 400 10.7 57 229 260
17 55 M 60 4.9 9 DCS–MRA 6/6 240 3.8 60 298 496
ADFL 5 atrial defibrillation limit; AF 5 atrial fibrillation; CS 5 coronary sinus; DCS 5 distal coronary sinus; IES 5 interelectrode spacing; LA 5 left atrium; LRA 5 low
anterolateral right atrium; MCS 5 mid-coronary sinus; MRA 5 midanterolateral right atrium; RA 5 right atrium; SR 5 sinus rhythm.
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the RA and CS electrodes in most patients (all but two)
were in the mid anterolateral RA and distal CS (Fig. 2B).
Atrial signals for AF detection. The mean RA-CS signal
amplitude during sinus rhythm was significantly greater
than that of AF (484 6 229 mV vs. 274 6 88 mV,
p , 0.001). Atrial fibrillation detection testing with the
IAD was performed 313 times. During sinus rhythm, 119
tests of AF detection were performed and accurate
identification of sinus rhythm was always achieved (0%
false positive rate). During AF, 194 tests of AF detection
were performed, and there were 43 episodes (22%) of
incomplete AF detection in six patients due to low
RA-CS signal amplitude. All of these patients had
successful AF detection after repeated testing or after
reprogramming the gain setting. For the 151 tests during
AF, all episodes were detected approximately (100% true
positive rate). Overall, the atrial signal from the RA and
CS electrodes of the Solo lead had sufficient amplitudes
for AF detection by the IAD during sinus rhythm and
AF.
Transvenous atrial defibrillation. R-wave synchroniza-
tion was accurate in all the patients studied. Successful
cardioversion was achieved in 16 of the 17 patients (94%). A
total of 142 shocks were delivered (6.8 6 3.6 shocks/
patient) during the procedure. The mean atrial defibrillation
threshold was 320 6 70 V with a corresponding energy of
5.5 6 2.7 J. The mean shock impedance was 67 6 9 V. The
procedure did not induce ventricular arrhythmia nor result
in other complications.
Effects of electrodes location. The efficacy of the Solo lead
for atrial sensing and defibrillation at low anterolateral
RA–mid-CS electrodes location (group 1) was compared
with that at mid anterolateral RA–distal CS (group 2)
(Table 2). There were no significant differences between the
two groups regarding their clinical characteristics, successful
rate of cardioversion and the percentage ratio of the two
biphasic shock waveforms (3/3 ms and 6/6 ms) used.
However, patients in group 1 had significantly lower atrial
signal amplitudes during both AF and sinus rhythm (Fig.
3A) and significantly higher atrial defibrillation thresholds
as compared with patients in group 2. With respect to signal
amplitudes, there was a significant interaction between
electrode location and rhythm (p , 0.05), denoting that the
signal amplitude changes associated with rhythm (AF vs.
SR) were greater for group 2 (mid anterolateral RA–distal
CS). The shock impedance was also significantly lower in
group 1 as compared with group 2. Furthermore, four of
eight patients (50%) in group 1 experienced clinically
significant diaphragmatic stimulation during shock delivery.
All of them started to have diaphragmatic stimulation at the
lowest energy of the defibrillation shock (i.e., 180 V). Thus,
the presence of the diaphragmatic stimulation was indepen-
dent of the strength of the shock. In contrast, none of the
patients in group 2 had diaphragmatic stimulation during
defibrillation at any intensity of shock delivered.
Effects of changes in posture. In all patients, fluoroscopic
examination of the lead location during changes in posture
from supine to upright revealed no significant changes in
lead location nor any lead dislodgments. There was no
significant differences in the RA-CS signal amplitudes
comparing supine and upright postures during both AF and
sinus rhythm (Fig. 3B). There was a significant interaction
between posture and rhythm (p , 0.05) that can be
visualized on the graph: supine posture is associated with a
Figure 2. Posteroanterior (PA) view of cine images showing
different electrode locations of the Solo lead when different
interelectrode spacings were used. (A) Solo lead with 5-cm
interelectrode spacing resulted in the electrodes positioned in low
right atrium and midcoronary sinus. (B) Solo lead with 9-cm
interelectrode spacing allowed optimal positioning of the elec-
trodes to the mid-right atrium and distal coronary sinus.
1977JACC Vol. 33, No. 7, 1999 Tse et al.
June 1999:1974–80 Single-Pass Lead for Atrial Defibrillator
slightly lower signal amplitude than the upright posture
during AF that reverses during sinus rhythm.
DISCUSSION
Main findings. The results of the present study have
demonstrated the feasibility and efficacy of using an im-
plantable single-pass, dual-electrode lead for both AF de-
tection and defibrillation with an IAD. The atrial signals
from the RA-CS vector with this lead were of sufficient
amplitude for accurate AF detection. Successful cardiover-
sion of AF by the Solo lead was achieved in 94% of patients
with persistent AF with average threshold of 320 V, 5.5 J.
There were no clinically significant changes in the lead
location nor in the atrial signal amplitudes observed during
change in patient posture. Furthermore, the electrode loca-
tion of the Solo lead has a significant effect on its efficacy in
detection and defibrillation of AF; the electrodes should be
positioned to the mid anterolateral RA and distal CS by
using a lead with optimal interelectrode spacing.
Detection of AF. Location and configuration of the atrial
sensing electrodes are important determinants of the signal
characteristics during AF as compared with a more orga-
nized rhythm (13), due to the smaller signal amplitude
during AF (14). Furthermore, as the atria are activated
randomly with multiple simultaneous wavelets, signals re-
corded from a widely spaced bipole tend to appear more
“fibrillatory,” with a faster rate and more fractionation as
compared with those from a closely spaced bipole. Thus,
using a large surface area, widely spaced electrodes that are
capable of capturing atrial signals from multiple sites may
have an advantage for certain algorithms used to detect AF.
Previous studies (9–11) have demonstrated sufficient atrial
signal amplitudes for accurate AF detection can be achieved
using the RA-CS sensing vector recorded from large surface
area electrodes in the RA and CS.
Our results demonstrated that the atrial signals recorded
from the “floating” RA electrode and a distal CS electrode
on the Solo lead were of sufficient amplitude to allow
accurate detection of AF and sinus rhythm by the IAD.
Consistent with the results of a previous study (14), we
found that the atrial signal amplitude was significantly lower
during AF as compared with sinus rhythm. Changes in









Age (yr) 61 6 13 60 6 6 0.481
AF duration (mo) 28 6 16 21 6 15 0.276
Left atrial size (cm) 4.66 6 0.61 4.70 6 1.02 0.888
Ejection fraction (%) 65 6 8 57 6 16 0.236
Waveform (3/3 ms:6/6 ms) 5:4 2:6 0.637
ADFT (V) 368 6 44 278 6 63 0.005*
Energy (J) 6.93 6 3.09 4.18 6 1.57 0.036*
Impedance (V) 62 6 6 71 6 10 0.027*
RA-CS amplitude (mV):
AF 218 6 67 323 6 74 0.008*
SR 336 6 110 675 6 231 0.011*
*p values , 0.05.
ADFT 5 atrial defibrillation threshold; AF 5 atrial fibrillation; CS 5 coronary sinus; RA 5 right atrium; SR 5 sinus
rhythm.
Figure 3. Atrial signal amplitude detected by the Solo lead in right
atrial (RA) to coronary sinus (CS) vector during sinus rhythm (SR)
and atrial fibrillation (AF). (A) Comparison of the atrial signal
amplitudes between different electrode locations. *p , 0.05. Solid
bar 5 all; open bar 5 LRA-MCS; striped bar 5 MRA-DCS.
(B) Comparison of the atrial signal amplitude during supine and
upright posture. *p , 0.05. Solid bar 5 supine; open bar 5
upright. DCS 5 distal coronary sinus; LRA 5 mid-right atrium;
MCS 5 midcoronary sinus; MRA 5 mid-right atrium.
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atrial signal amplitude associated with different postures is
an important consideration when using a lead with a
floating atrial electrode for AF detection. A large inter- and
intraindividual variability of the atrial signal amplitude
when using a floating atrial electrode has been observed
during different postures and movements with other lead
systems (15,16). Our results have demonstrated that the
preformed spiral shape in the distal CS electrode of the Solo
lead has enhanced the stability of the electrodes both in the
CS and in the RA. In this study, no significant changes in
lead location nor in atrial signal amplitudes were observed
with changes in body posture.
More important, we observed that the locations of the
electrodes also have a significant impact on the sensed atrial
signal amplitude. The signal amplitude recorded using the
mid anterolateral RA–distal CS vector was significantly
larger than those recorded using the low anterolateral
RA–mid-CS vector during atrial fibrillation and sinus
rhythm. There are several possible explanations for this
finding. First, a wider signal detection vector between mid
anterolateral RA–distal CS as compared with the low
RA–mid anterolateral CS may increase the signal amplitude
by encompassing more of the atria, therefore sensing more
of the global signal from the atria. Second, the atrial signals
from low anterolateral RA–mid-CS vector may be more
contaminated by a large ventricular component, and some of
the atrial signals may be lost during blanking of the
ventricular signal. Because the ventricular signal was
blanked by the algorithm from which data were saved, we
were unable to test this hypothesis. Finally, there may exist
regional differences in the atrial signal amplitude within the
RA accounting for the differences due to far field versus near
field sensing. Previous studies have demonstrated that the
mid-RA is usually the best location for sensing atrial signals
when using floating atrial electrodes (17,18).
Transvenous atrial defibrillation. The successful applica-
tion of transvenous shock using a biphasic waveform and a
RA to CS shock vector for atrial defibrillation have led to
the development of an IAD for treatment of recurrent AF
(8,9). However, a disadvantage of the currently available
system is the need for a separate RA and CS lead to achieve
a satisfactory atrial defibrillation threshold, with implica-
tions for device battery longevity and patient tolerability
(1,3,10). The need for multiple lead placements may in-
crease the implantation procedure time, which may increase
the risk of perioperative complications. In addition, the
presence of more leads may increase the risk of late
complications such as lead dislodgments. Recent studies
have demonstrated a similar atrial defibrillation threshold
when comparing a temporary, single-pass transvenous cath-
eter and separate RA and CS catheters used for internal
cardioversion of atrial fibrillation (19–21), but the stability
and feasibility of a lead for permanent use remained uncer-
tain. Our results have confirmed the efficacy of a single-pass
lead for atrial defibrillation when used with an IAD. Using
the Solo lead, successful cardioversion was achieved in up to
94% of patients with a comparable atrial defibrillation
threshold and energy requirement as reported in previous
studies using conventional two-lead configuration (2–7).
We were also able to show the implant feasibility and
electrode/lead stability during changes in posture of this
implantable grade, single-pass lead for AF detection and
atrial defibrillation.
Consistent with a recent study (10), we found the
locations of the defibrillation electrodes have a significant
effect on the efficacy of atrial defibrillation. Insufficient
interelectrode spacing of the Solo lead resulted in subopti-
mal electrode locations, with the electrodes positioned to
low RA and mid-CS. These electrode locations associated
with this insufficient interelectrode spacing were associated
with a lower atrial sensing signal amplitude and a higher
defibrillation threshold and caused shock intensity–
independent diaphragmatic stimulation in up to 50% of
patients. The effect of interelectrode spacing on atrial signal
amplitude has been discussed previously. Similar to the
amplitude changes, the higher defibrillation threshold was
also probably due to having a smaller amount of fibrillating
tissue encompassed by the low anterolateral RA–mid-CS
vector compared with the mid anterolateral RA–distal CS
vector (1). In addition, the shorter distance between the
electrodes causes a lower shock impedance, probably due to
shunting of current through the blood resulting in fewer
areas of the atria reaching an adequate potential gradient to
achieve defibrillation. Last, it seems likely that a higher local
potential gradient in the posterior aspect of the heart due to
the location of the electrodes is the cause of the diaphrag-
matic stimulation. Thus, the interelectrode spacing of the
Solo lead should be adjusted in a given patient so that the
electrodes are positioned in the mid anterolateral RA and in
the distal CS to achieve optimal AF detection and lowest
atrial defibrillation thresholds and to avoid diaphragmatic
stimulation.
Conclusions. A simplified lead configuration, comprising a
single-pass, dual-electrode atrial defibrillation lead and a
standard RV pacing lead, can be used with an implantable
atrial defibrillator. This new lead system is effective for both
atrial fibrillation detection and atrial defibrillation. The
defibrillation electrodes on the single-pass lead should be
positioned in the mid-RA and distal CS by using a lead
with optimal interelectrode spacing, thereby achieving op-
timal atrial sensing and defibrillation thresholds, without
causing diaphragmatic stimulation.
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